Patimaporn Wongprompitak

Dr. Patimaporn Wongprompitak

Department of Immunology, Faculty of medicine siriraj hospital, Mahidol university, Bangkok, Krung Thep Maha Nakhon, Thailand
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2017 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
TJTeerayuth Jiamjariyapon
Teerayuth Jiamjariyapon
AIAtiporn Ingsathit
Atiporn Ingsathit
KPKrit Pongpirul
Krit Pongpirul
KVKotcharat Vipattawat
Kotcharat Vipattawat
SKSuphattra Kanchanakorn
Suphattra Kanchanakorn
KTKriang Tungsanga
Kriang Tungsanga
In developing countries, renal specialists are scarce and physician-to-patient contact time is limited. While conventional hospital-based, physician-oriented approach has been the main focus of chronic kidney disease (CKD) care, a comprehensive multidisciplinary health care program (Integrated CKD Care) has been introduced as an alternate intervention to delay CKD progression in a community population. The main objective is to assess effectiveness of Integrated CKD Care in delaying CKD progression. We carried out a community-based, cluster randomized controlled trial. Four hundred forty-two stage 3-4 CKD patients were enrolled. In addition to the standard treatments provided to both groups, the patients in the intervention group also received “Integrated CKD Care”. This was delivered by a multidisciplinary team of hospital staff in conjunction with a community CKD care network (subdistrict healthcare officers and village health volunteers) to provide group counseling during each hospital visit and quarterly home visits to monitor compliance with the treatment. Duration of the study was 2 years. The primary outcome was difference of mean eGFR between the intervention and the control groups over the study period. The mean difference of eGFR over time in the intervention group was significantly lower than the control group by 2.74 ml/min/1.73 m2 (95%CI 0.60–4.50, p = 0.009). Seventy composite clinical endpoints were reported during the study period with significantly different incidences between the control and the intervention groups (119.1 versus 69.4 per 1000 person-years; hazard ratio (HR) 0.59, 95% CI 0.4–0.9, p = 0.03). Integrated CKD Care can delay CKD progression in resource-limited settings. ( NCT01978951 ). Prospectively registered as of December 8, 2012.

1 March 2009 in Journal of Immunological Methods
Verified
Journal Article
Closed access
KEKristin Eske
Kristin Eske
KBKatrin Breitbach
Katrin Breitbach
Jens KöhlerJens Köhler
Jens Köhler
Patimaporn WongprompitakPatimaporn Wongprompitak
Patimaporn Wongprompitak
ISIvo Steinmetz
Ivo Steinmetz

1 April 2009 in Infection and Immunity
Verified
Journal Article
Closed access
KBKatrin Breitbach
Katrin Breitbach
GSGuang Wen Sun
Guang Wen Sun
Jens KöhlerJens Köhler
Jens Köhler
KEKristin Eske
Kristin Eske
Patimaporn WongprompitakPatimaporn Wongprompitak
Patimaporn Wongprompitak
ISIvo Steinmetz
Ivo Steinmetz
The gram-negative rod Burkholderia pseudomallei is the causative agent of melioidosis, a potentially fatal disease which is endemic in tropical and subtropical areas. The bacterium multiplies intracellularly within the cytosol, induces the formation of actin tails, and can spread directly from cell to cell. Recently, it has been shown that B. pseudomallei can induce caspase-1-dependent cell death in macrophages. The aim of the present study was to further elucidate the role of caspase-1 during B. pseudomallei infection. In vivo experiments with caspase-1 −/− mice revealed a high susceptibility to B. pseudomallei challenge. This phenotype was associated with a significantly higher bacterial burden 2 days after infection and decreased gamma interferon (IFN-γ) and interleukin-18 cytokine levels 24 h after infection compared to control animals. caspase-1 −/− bone marrow-derived macrophages (BMM) exhibited strong caspase-3 expression and reduced cell damage compared to wild-type (WT) cells during early B. pseudomallei infection, indicating “classical” apoptosis, whereas WT BMM showed signs of rapid caspase-1-dependent cell death. Moreover, we found that caspase-1 −/− BMM had a strongly increased bacterial burden compared to WT cells 3 h after infection under conditions where no difference in cell death could be observed between both cell populations at this time point. We therefore suggest that caspase-1-dependent rapid cell death might contribute to resistance by reducing the intracellular niche for B. pseudomallei , but, in addition, caspase-1 might also have a role in controlling intracellular replication of B. pseudomallei in macrophages. Moreover, caspase-1-dependent IFN-γ production is likely to contribute to resistance in murine melioidosis.

1 April 2013 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
VDVeasna Duong
Veasna Duong
TMTrinh Thi Xuan Mai
Trinh Thi Xuan Mai
KBKim Blasdell
Kim Blasdell
LLLe Viet Lo
Le Viet Lo
CMClaire Morvan
Claire Morvan
PBPhilippe Buchy
Philippe Buchy

1 April 2015 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
Patimaporn WongprompitakPatimaporn Wongprompitak
Patimaporn Wongprompitak
VDVeasna Duong
Veasna Duong
WAWichittra Anukool
Wichittra Anukool
LSLay Sreyrath
Lay Sreyrath
TMTrinh Thi Xuan Mai
Trinh Thi Xuan Mai
RFRoger Frutos
Roger Frutos

11 July 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SNSuvimol Niyomnaitham
Suvimol Niyomnaitham
Zheng Quan TohZheng Quan Toh
Zheng Quan Toh
Patimaporn WongprompitakPatimaporn Wongprompitak
Patimaporn Wongprompitak
LJLaddawan Jansarikit
Laddawan Jansarikit
KSKanjana Srisutthisamphan
Kanjana Srisutthisamphan
KCKulkanya Chokephaibulkit
Kulkanya Chokephaibulkit
We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 regimens. Participants were randomized to one of seven groups that received two-dose homologous BNT162b2 or heterologous combinations of CoronaVac, ChAdOx1 nCoV-19 and BNT162b2, with 4 weeks interval. A total of 210 participants were enrolled, 30 in each group. Median age of participants was 38 (19–60) years, and 108/210 (51.43%) were female. Overall adverse events after the second dose were mild to moderate. We found that groups that received BNT162b2 as second dose induced the highest anti-receptor binding domain IgG response against the ancestral strain [BNT162b2: geometric mean concentration (GMC) 2133–2249 BAU/mL; ChAdOx1 nCoV-19: 851–1201; CoronaVac: 137–225 BAU/mL], neutralizing antibodies (NAb) against Beta and Delta, and interferon gamma response. All groups induced low to negligible NAb against Omicron after second dose. A BNT162b2 booster (third dose) following heterologous CoronaVac and ChAdOx1 nCoV-19 regimens induced >140-fold increase in NAb titers against Omicron. Our findings indicate that heterologous regimens using BNT162b2 as the second dose may be an alternative schedule to maximize immune response. While heterologous two-dose schedules induced low NAb against Omicron, the use of an mRNA vaccine booster dose substantially increased the Omicron response. These findings are relevant for low-income countries considering heterologous primary and booster COVID-19 vaccine schedules.